臨床研究等提出・公開システム

A phase III, randomized, active-comparator, observer-blind, non-inferiority study to demonstrate the immunogenicity and safety of DS-5670d (monovalent: omicron XBB.1.5) in children 5 through 11 years of age

A phase III, randomized, active-comparator, observer-blind, non-inferiority study to demonstrate the immunogenicity and safety of DS-5670d (monovalent: omicron XBB.1.5) in children 5 through 11 years of age

Inoguchi Akihiro

Daiichi Sankyo Co., Ltd.

1-2-58, Hiromachi, Shinagawa-ku, Tokyo

dsclinicaltrial@daiichisankyo.co.jp

Contact for Clinical Trial Information

Daiichi Sankyo Co., Ltd.

1-2-58, Hiromachi, Shinagawa-ku, Tokyo

+81-3-6225-1111

dsclinicaltrial@daiichisankyo.co.jp

Pending

Jan. 05, 2024

Interventional

randomized controlled trial

double blind

active control

parallel assignment

prevention purpose

1) Subjects aged 5 to 11 years at the time of informed consent.
2) Having provided written consent to study participation via the legal representative.
3) Able to comply with the rules of the study, record symptoms via electronic diary by his/her legal representative, undergo physical examinations and tests that are specified in the protocol, and report symptoms or other issues (report from his/her legal representative to be available).

1) Having any serious cardiovascular, renal, hepatic, blood, neuropsychiatric, developmental disorder, thrombocytopenia, or coagulopathy.
2) Having a medical history of vaccination-related convulsions or epilepsy.
3) Having a concurrent or medical history of myocarditis or pericarditis.
4) Having tested positive within 3 months before informed consent for SARS-CoV-2 infection (based on RT-PCR, other nucleic acid detection methods, or SARS-CoV-2 antigen test), or having been diagnosed with COVID-19 based on a physician's examination.
5) Having been diagnosed with immunodeficiency in the past or having a close relative with congenital immunodeficiency.
6) Having symptoms suspected of SARS-CoV-2 infection (eg, respiratory symptoms, headache, malaise, anosmia, dysgeusia, pharyngeal pain) at the time of informed consent.
7) Having tested positive for SARS-CoV-2 antigen test at the time of eligibility evaluation.
8) Having tested positive for SARS-CoV-2 antibody test at the time of eligibility evaluation, with symptoms suspected ofSARS-CoV-2 infection (eg, respiratory symptoms, headache, malaise, anosmia, dysgeusia, pharyngeal pain) within 3 months before informed consent.

Both

Prevention of infection due to SARS-CoV-2

A dose of either DS-5670d (0.2 mL) or Comirnaty IM (0.2 mL) will be intramuscularly administered to the deltoid muscle of the upper arm.

-The GMT of blood neutralising activity against SARS-CoV-2 (Omicron XBB.1.5) at 4 weeks after the administration in children 5 through 11 years of age with at least one of SARS-CoV-2 infection history and SARS-CoV-2 vaccination history.
- The seroresponse rate of blood neutralising activity against SARS-CoV-2 (Omicron XBB.1.5) at 4 weeks after the administration in children 5 through 11 years of age with at least one of SARS-CoV-2 infection history and SARS-CoV-2 vaccination history.

-The GMT of blood neutralising activity against SARS-CoV-2 (Omicron XBB.1.5) at 4 weeks after the administration in children 5 through 11 years of age regardless of SARS-CoV-2 infection history and SARS-CoV-2 vaccination history.
-The seroresponse rate of blood neutralising activity against SARS-CoV-2 (Omicron XBB.1.5) at 4 weeks after the administration in children 5 through 11 years of age regardless of SARS-CoV-2 infection history and SARS-CoV-2 vaccination history.

No

none